Piper Sandler Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $40
Pliant Therapeutics (PLRX) Gets a Buy From Piper Sandler
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Pliant Therapeutics Analyst Ratings
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential
Leerink Partners Initiates Pliant Therapeutics(PLRX.US) With Buy Rating, Announces Target Price $33
Oppenheimer Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $45
CCORF Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $43
Pliant Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Pliant Therapeutics, Raises Price Target to $38
Pliant Therapeutics: A Buy Rating on Robust Clinical Progress and Promising Drug Prospects
Pliant Therapeutics (PLRX) Receives a Buy From Oppenheimer
Oppenheimer Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $45
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Allogene Therapeutics (ALLO)
TD Cowen Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
Piper Sandler Sticks to Its Buy Rating for Pliant Therapeutics (PLRX)
Pliant Therapeutics Analyst Ratings
TD Cowen Remains a Buy on Pliant Therapeutics (PLRX)
Pliant Therapeutics Analyst Ratings